国产成人一区二区三区四区五区_日韩精品无码免费视频不卡_最近日本电影影视在线观看免费_jjzz在线免费观看_欧美亚日韩综合色_外国黄色视频九九_亚洲无码熟妇淫荡多汁水冲_人人狠狠综合久久88亚洲_成品人抖音直播app_95后国产对白影音先锋互動交流

In November 2021, CR Pharmaceutical fully completed the acquisition of Boya Bio-pharmaceutical, with a shareholding ratio of 28.86% and a voting right of 40.01%, realizing a strategic development in the field of blood products.

In September 2021, CR Jiangzhong acquired a 51% stake in Hays Pharma Limited, adding high-quality varieties to its original gastroenterology products.

In July 2021, CR Pharmaceutical acquired a 10% stake in Immunotech Biopharm Ltd. for strategic development in the field of cellular immunotherapy.

In February 2021, CR Double-Crane acquired a 33.3% stake in Zhejiang Peptites Biotech Co., Ltd. by means of capital increase, establishing its presence in the peptide field.

2020

The class I innovative drug NIP046 developed by CR Pharmaceutical was approved for clinical trial targeting rheumatoid arthritis indications.

The class I innovative drug NIP292 obtained the Orphan Drug Designation (ODD) issued by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

CR Double-Crane acquired 38.75% of the stake of Dongying Tiandong Pharmaceutical Co., Ltd.

2019

CR Pharmaceutical completed the reorganization of CR Jiangzhong. By then, Jiangxi Jiangzhong Pharmaceutical (Group) Co., Ltd. (Jiangzhong Group) was renamed China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (CR Jiangzhong) and was listed as a first-level profit center in CR Pharmaceutical’s management sequence.

CR Sanjiu, CR Double-Crane, and Dong-E-E-Jiao were officially included in the FTSE Russell Global Index.

The class I innovative drug NIP292 for the treatment of idiopathic pulmonary fibrosis (IPF) obtained the approval of FDA for Phase I clinical trial.

CR Double-Crane held a meeting for celebrating the company’s 80th anniversary of its foundation in Beijing.

2018

CR signed a strategic cooperation agreement with the People’s Government of Jiangxi for the reorganization of Jiangzhong Group. CR Pharmaceutical acquired or subscribed over 51% stake of Jiangzhong Group equity through cash or assets.

CR Pharmaceutical was selected as a constituent stock of the Hang Seng Corporate Sustainability Benchmark Index.

CR Sanjiu and Dong-E-E-Jiao were listed in the MSCI Emerging Market Index.

CR Double-Crane acquired Hunan Xiangzhong Pharmaceutical Co., Ltd.

2017

CR Pharmaceutical was listed as a constituent stock in the Hang Seng Composite LargeCap Index, the Hang Seng Mainland Healthcare Index, the Hang Seng Healthcare Index, the Hang Seng China-Affiliated Corporations Index, the Hang Seng China (Hong Kong-listed) 100 Index, the FTSE Global Equity Index Series (Large Cap), the FTSE All-World Index Series, the FTSE Global All Cap Index, and the MSCI China Index.

CR Sanjiu acquired 65% of the equity of Jilin Jinfukang Pharmaceutical Co., Ltd. and 65% of the equity of Shandong Shenghai Health Products Co., Ltd. CR Double-Crane acquired 100% of the equity of Hainan Zhong Hua Lian He Pharmaceutical. Co., Ltd.

2016

We completed the acquisition of 100% interest in CR Pharmaceutical Retail Group which wholly owned CR Care, a company principally engaged in pharmacy business in China and Hong Kong.

2015

CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2015 (中國(guó)醫(yī)藥行業(yè)企業(yè)集團(tuán)十強(qiáng))” at the ChemPharm Annual Summit 2015(2015中國(guó)化學(xué)制藥行業(yè)年度峰會(huì)).

2014

Our Company ranked No.4 among the “Top 100 Enterprises in the PRC Pharmaceutical Industry of 2013 (2013年度中國(guó)醫(yī)藥工業(yè)百?gòu)?qiáng)企業(yè)”.

CR Pharmaceutical Holdings was awarded the “Top 10 PRC Pharmaceutical Group of 2014 (中國(guó)醫(yī)藥行業(yè)企業(yè)集團(tuán)十強(qiáng))” at the ChemPharm Annual Summit 2014 (2014中國(guó)化學(xué)制藥行業(yè)年度峰會(huì)).

The Beijing Pharmaceutical Group Industry-University-Research Alliance (北京醫(yī)藥集團(tuán)產(chǎn)學(xué)研聯(lián)盟) led by our Company under the Eleventh-Five Year Plan was successfully completed and accepted.

2013

BEID Fund became a shareholder of our Company.

The total assets and revenue of our Group for the year respectively exceeded HK$100 billion for the first time

2012

CR Pharmaceutical Commercial became a wholly-owned subsidiary of our Company.

We acquired the remaining 52.72% interest in CR Zizhu to further develop our product portfolio and enhance our market penetration.

Pharmaceutical R&D Center became our wholly-owned subsidiary.

We established the Health Institute of China Resources University (華潤(rùn)大學(xué)健康學(xué)院) in June 2012.

2011

We acquired the remaining 50% interest in Beijing Pharmaceutical, and thereafter Beijing Pharmaceutical became a wholly-owned subsidiary of our company.

Beijing Pharmaceutical investment became a Share holder of our Company.

We successfully completed 11 mergers and acquisitions in Beijing, Jiangsu, Henan and other provinces, which further developed our core businesses and enhanced our presence in the pharmaceutical market in China.

2010

Our company entered into a strategic cooperation agreement with the China Academy of Medical Sciences (中國(guó)醫(yī)學(xué)科學(xué)院) to strengthen the research and development capabilities of our Group.

We acquired 50% interest in Beijing Pharmaceutical from CRC.

CR Double-Crane became our non-wholly owned subsidiary following the completion of acquisition of 50% interest in Beijing Pharmaceutical.

2008

We acquired 56.62% interest in CR Dong-E from CRC, thereby controlling 23.14% interest in Dong-E-E-Jiao, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing of E Jiao (donkey-hide gelatin) products.

We completed the acquisition of 66.98% interest in CR Sanjiu, a company listed on the Shenzhen Stock Exchange and principally engaged in the manufacturing and sale of OTC drugs and Chinese prescription medicine.

2007

Our Company was incorporated in Hong Kong.

2006

CRC was engaged in the restructuring of China Worldbest, and acquired 50% interest in Beijing Pharmaceutical.

2004

CRC set up CR Done-E with Liaocheng SASAC (the State-Owned Assets Supervision and Administration Commission of the State Council).

1983

Our controlling shareholder, China Resources Holdings, was incorporated in Hong Kong.

1953

China Resources Company (華潤(rùn)公司) started to export medicines and medical devices to mainland China.

1948

Liow & Company (聯(lián)合行) was renamed as China Resources Company (華潤(rùn)公司)

1938

Liow & Company (聯(lián)合行), the predecessor of China Resources Holdings, our controlling shareholder, was founded.